2,956 Shares in Astrazeneca Plc $AZN Purchased by Advisortrust Partners LLC

Advisortrust Partners LLC acquired a new stake in Astrazeneca Plc (NYSE:AZN) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 2,956 shares of the company’s stock, valued at approximately $519,000.

Several other institutional investors have also added to or reduced their stakes in the business. Arrowstreet Capital Limited Partnership increased its stake in shares of Astrazeneca by 552.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 5,547,597 shares of the company’s stock worth $973,603,000 after purchasing an additional 4,697,895 shares in the last quarter. Bank of Montreal Can lifted its stake in shares of Astrazeneca by 344.6% during the 3rd quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock valued at $266,841,000 after buying an additional 2,695,793 shares in the last quarter. Citigroup Inc. boosted its holdings in Astrazeneca by 65.3% in the 4th quarter. Citigroup Inc. now owns 6,154,760 shares of the company’s stock worth $1,080,160,000 after buying an additional 2,431,890 shares during the period. Holocene Advisors LP grew its stake in Astrazeneca by 41.8% in the 3rd quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock valued at $470,232,000 after buying an additional 1,807,565 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich raised its holdings in Astrazeneca by 11,190.9% during the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,806,877 shares of the company’s stock valued at $317,107,000 after acquiring an additional 1,790,874 shares during the period. 20.35% of the stock is owned by hedge funds and other institutional investors.

Astrazeneca Trading Down 0.0%

Astrazeneca stock opened at $174.87 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. Astrazeneca Plc has a fifty-two week low of $137.23 and a fifty-two week high of $212.71. The stock has a market cap of $271.20 billion, a P/E ratio of 26.26, a PEG ratio of 1.52 and a beta of 0.25. The firm’s fifty day moving average price is $186.62 and its 200-day moving average price is $186.27.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The company had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. Equities research analysts forecast that Astrazeneca Plc will post 9.39 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. DZ Bank raised Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. UBS Group reiterated a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Morgan Stanley reissued an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Wall Street Zen upgraded Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 9th. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $205.33.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.